NATIONAL INSTITUTES OF HEALTH

Eolas Therapeutics has secured full development rights to AZD4041 from AstraZeneca, a highly selective orexin-1 receptor antagonist targeting opioid use disorder and other substance use disorders.

PDS Biotech's PDS01ADC met RECIST v1.1 criteria for expansion to Stage 2 of a Phase 2 trial in metastatic colorectal cancer, achieving at least 6 objective responses in 9 patients.

MIT engineers have developed an implantable device that automatically administers glucagon to prevent life-threatening hypoglycemic episodes in diabetics, with testing in mice showing blood sugar stabilization within 10 minutes.

Scientists at The Herbert Wertheim UF Scripps Institute developed a novel antibody-drug conjugate combining tiancimycin, a natural compound from soil microbes, with a "double-decker" antibody targeting CD79b for diffuse large B cell lymphoma treatment.

UCLA-led researchers received a $3.5 million NIH grant to develop treatments for mpox, focusing on a more virulent strain causing increased deaths among children in the Democratic Republic of Congo.

The Indian Council of Medical Research (ICMR) and Panacea Biotec have initiated India's first Phase 3 clinical trial for an indigenous tetravalent dengue vaccine called DengiAll.

Quiver Bioscience received a $2.15 million Phase II SBIR grant from the National Institute of Neurological Disease and Stroke to develop an integrated platform for predicting safety of CNS-targeted antisense oligonucleotide therapeutics.

AN2 Therapeutics completed a 200-patient observational study in acute melioidosis, revealing a striking mortality rate of nearly 40% by Day 90 despite standard of care treatment.

The University of Kansas Medical Center received a five-year, $31 million NIH grant to coordinate pediatric clinical trials across 18 rural and underserved sites, marking the largest award in the institution's history.

University of Oxford researchers have developed a programmable microcapsule delivery system that enables complete malaria vaccination in a single injection, eliminating the need for booster visits.